Literature DB >> 1652938

The presence of atrial-natriuretic-factor receptors of ANF-R2 subtype in rat platelets. Coupling to adenylate cyclase/cyclic AMP signal-transduction system.

M B Anand-Srivastava1, J Gutkowska, M Cantin.   

Abstract

The effect of atrial natriuretic factor (ANF) on adenylate cyclase activity was studied in rat platelet membranes. ANF-(99-126)-, -(101-126)-, -(103-126)- and -(103-123)-peptide inhibited adenylate cyclase activity in a concentration-dependent manner with an order of potency of ANF-(103-123)-peptide greater than ANF-(99-126)-peptide greater than ANF-(101-126)-peptide greater than ANF-(103-126)-peptide. ANF-(103-123)-peptide and ANF-(99-126)-peptide inhibited the enzyme activity by about 50-55%, with an apparent Ki between 0.1 and 0.5 nM, and ANF-(101-126)-peptide inhibited the enzyme activity by about 35%, with an apparent Ki between 1 and 3 nM. On the other hand, ANF-(103-126)-peptide was the least potent and inhibited the adenylate cyclase activity by about 30% (Ki approximately 10 nM). The inhibitory effect of ANF on adenylate cyclase was also dependent on the presence of guanine nucleotides and was attenuated by amiloride and pertussis toxin. The stimulatory effects of various agonists such as N-ethylcarboxamideadenosine, prostaglandin E1, isoprenaline and forskolin on adenylate cyclase were also inhibited by ANF to various extents; however, the stimulations were not completely abolished. In addition, 125I-labelled ANF-(99-126)-peptide bound specifically to rat platelet membranes. The binding of 125I-ANF was competitively inhibited in a concentration-dependent manner by the unlabelled peptides which were used for adenylate cyclase inhibition. ANF-(103-123)-peptide, ANF-(99-126)-peptide and ANF-(101-126)-peptide were almost equipotent [IC50 (median inhibitory concentration) = 0.1-1 nM], and ANF-(103-126)-peptide was the least potent (IC50 approximately 10 nM). Scatchard analysis of the data revealed the presence of a single class of binding sites of high affinity (Kd approximately 120 pM). Affinity cross-linking of 125I-ANF-(99-126)-peptide to its binding sites in rat platelet membranes and analysis by SDS/PAGE followed by autoradiography showed a predominant labelling of a protein band with an apparent Mr of 66,000. These data indicate the presence of only ANF-R2 (low-Mr) receptors in platelets and suggest that these receptors may be coupled to the adenylate cyclase system.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1652938      PMCID: PMC1151470          DOI: 10.1042/bj2780211

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  38 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Activation and stabilization of cardiac adenylate cyclase by GTP analog and fluoride.

Authors:  F F Snyder; G I Drummond
Journal:  Arch Biochem Biophys       Date:  1978-01-15       Impact factor: 4.013

3.  A highly sensitive adenylate cyclase assay.

Authors:  Y Salomon; C Londos; M Rodbell
Journal:  Anal Biochem       Date:  1974-04       Impact factor: 3.365

4.  Characterization by affinity cross-linking of a receptor for atrial natriuretic peptide in cultured human thyroid cells associated with reductions in both adenosine 3',5'-monophosphate production and thyroglobulin secretion.

Authors:  Y C Tseng; S Lahiri; D F Sellitti; K D Burman; J C D'Avis; L Wartofsky
Journal:  J Clin Endocrinol Metab       Date:  1990-02       Impact factor: 5.958

5.  Ring-deleted analogs of atrial natriuretic factor inhibit adenylate cyclase/cAMP system. Possible coupling of clearance atrial natriuretic factor receptors to adenylate cyclase/cAMP signal transduction system.

Authors:  M B Anand-Srivastava; M R Sairam; M Cantin
Journal:  J Biol Chem       Date:  1990-05-25       Impact factor: 5.157

6.  Amiloride interacts with guanine nucleotide regulatory proteins and attenuates the hormonal inhibition of adenylate cyclase.

Authors:  M B Anand-Srivastava
Journal:  J Biol Chem       Date:  1989-06-05       Impact factor: 5.157

7.  Characterization of specific receptors for atrial natriuretic factor in bovine adrenal zona glomerulosa.

Authors:  A De Léan; J Gutkowska; N McNicoll; P W Schiller; M Cantin; J Genest
Journal:  Life Sci       Date:  1984-12-03       Impact factor: 5.037

8.  Atrial natriuretic factor inhibits adenylate cyclase activity.

Authors:  M B Anand-Srivastava; D J Franks; M Cantin; J Genest
Journal:  Biochem Biophys Res Commun       Date:  1984-06-29       Impact factor: 3.575

9.  Atrial natriuretic factor selectively activates particulate guanylate cyclase and elevates cyclic GMP in rat tissues.

Authors:  S A Waldman; R M Rapoport; F Murad
Journal:  J Biol Chem       Date:  1984-12-10       Impact factor: 5.157

10.  Neuromodulatory effects of atrial natriuretic factor are independent of guanylate cyclase in adrenergic neuronal pheochromocytoma cells.

Authors:  J G Drewett; R J Ziegler; G J Trachte
Journal:  J Pharmacol Exp Ther       Date:  1990-11       Impact factor: 4.030

View more
  5 in total

1.  Possibility of age regulation of the natriuretic peptide C-receptor in human platelets.

Authors:  D Giannessi; M G Andreassi; S Del Ry; A Clerico; M G Colombo; N Dini
Journal:  J Endocrinol Invest       Date:  2001-01       Impact factor: 4.256

2.  Proliferative response of human and minipig smooth muscle cells after coronary angioplasty to growth factors and platelets.

Authors:  C Unterberg; T Meyer; V Wiegand; H Kreuzer; A B Buchwald
Journal:  Basic Res Cardiol       Date:  1996 Nov-Dec       Impact factor: 17.165

Review 3.  Natriuretic peptides in cardiometabolic regulation and disease.

Authors:  Nora E Zois; Emil D Bartels; Ingrid Hunter; Birgitte S Kousholt; Lisbeth H Olsen; Jens P Goetze
Journal:  Nat Rev Cardiol       Date:  2014-05-13       Impact factor: 32.419

4.  Defective ANF-R2/ANP-C receptor-mediated signalling in hypertension.

Authors:  J Marcil; M B Anand-Srivastava
Journal:  Mol Cell Biochem       Date:  1995 Aug-Sep       Impact factor: 3.396

5.  Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.